Literature DB >> 2412490

Activated interferon system in healthy homosexual men.

S Levin, T Hahn, Z T Handzel, E Galili-Wiesstub, V Bregman, R Myer, M Tinowitz, Y Altman, N Barzilai, Y Brenner.   

Abstract

More than 50% of a group of healthy homosexuals in Israel were found to have an activated interferon (IFN) system as evidenced by markedly elevated blood IFN levels, increased in vitro production of IFN by unstimulated peripheral blood mononuclear cells and HuIFN-alpha and HuIFN-gamma production by appropriately stimulated cells, and a surprisingly high incidence of an antiviral state of cells. This pattern resembles that found in persons with acute viral illness, and is unlike that found in normal healthy controls. The type of IFN in the blood was found to be unusual in that it was mainly HuIFN-alpha, pH 2-labile, a type of IFN found in certain collagen diseases as well as in homosexual men suffering from Kaposi's sarcoma or lymphadenopathy. Natural killer (NK) cytotoxic activity was found to be somewhat lower than that found in normal controls, although no correlation was found between blood IFN levels and NK activity. Mean (2'-5')-oligoisoadenylate synthetase levels in cell extracts were intermediate between normal controls and patients with viral illness. Likewise no correlation was found between enzyme levels and blood IFN levels. The highly activated IFN system found in certain homosexuals, as well as the increased spontaneous production of IFN by unstimulated mononuclear cells, suggest the possibility of the presence of a virus, active or latent, in these individuals. This virus could be a retrovirus such as HTLV-III or LAV which have recently been isolated from AIDS patients. The special type of IFN present could be the response to a novel virus in an unusual situation. On the basis of recent reports, we speculate that homosexuals with highly activated IFN systems who produce pH 2-labile HuIFN-alpha could be at increased risk for developing AIDS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412490      PMCID: PMC7134039          DOI: 10.1016/0166-3542(85)90027-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


Table III

Clinical Applications of Antiviral Agents in Respiratory Viral Infection

Effective for
VirusProphylaxisTreatment
Influenza AAmantadine (oral)Amantadine (oral)*
Rimantadine (oral)Rimantadine (oral)*
Ribavirin (aerosol)*
Influenza BRibavirin (aerosol)*
Resp. syncytialRibavirin (aerosol)
RhinovirusIFN-a2 (intranasal)
*Efficacy has been established only in uncomplicated disease
  31 in total

1.  Influenza A prophylaxis with amantadine in a boarding school.

Authors:  D K Payler; P A Purdham
Journal:  Lancet       Date:  1984-03-03       Impact factor: 79.321

2.  Intranasal interferon for contact prophylaxis against common cold in families.

Authors:  C Herzog; M Just; R Berger; L Havas; M Fernex
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

3.  Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2.

Authors:  F G Hayden; S E Mills; M E Johns
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

4.  A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.

Authors:  R Dolin; R C Reichman; H P Madore; R Maynard; P N Linton; J Webber-Jones
Journal:  N Engl J Med       Date:  1982-09-02       Impact factor: 91.245

5.  Airway hyperreactivity and peripheral airway dysfunction in influenza A infection.

Authors:  J W Little; W J Hall; R G Douglas; G S Mudholkar; D M Speers; K Patel
Journal:  Am Rev Respir Dis       Date:  1978-08

6.  Prevention of Russian influenza by amantadine.

Authors:  A S Monto; R A Gunn; M G Bandyk; C L King
Journal:  JAMA       Date:  1979-03-09       Impact factor: 56.272

7.  Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.

Authors:  F G Hayden; H E Hoffman; D A Spyker
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

8.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.

Authors:  C B Hall; J T McBride; E E Walsh; D M Bell; C L Gala; S Hildreth; L G Ten Eyck; W J Hall
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245

9.  Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.

Authors:  F G Hayden; J M Gwaltney
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

10.  Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants.

Authors:  L H Taber; V Knight; B E Gilbert; H W McClung; S Z Wilson; H J Norton; J M Thurson; W H Gordon; R L Atmar; W R Schlaudt
Journal:  Pediatrics       Date:  1983-11       Impact factor: 7.124

View more
  1 in total

1.  Immune impairments and antibodies to HTLVIII/LAV in asymptomatic male homosexuals in Israel: relevance to the risk of acquired immune deficiency syndrome (AIDS).

Authors:  Z Bentwich; C Saxinger; Z Ben-Ishay; R Burstein; Y Berner; M Pecht; N Trainin; S Levin; Z T Handzel
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.